Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Fabrinet (FN) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance

Oruka Therapeutics Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Fabrinet vs Oruka Therapeutics Inc. Common Stock — how do they compare? Fabrinet trades at $384 (market cap $15.33B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Fabrinet is far larger — about 3× Oruka Therapeutics Inc. Common Stock's market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, Fabrinet nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fabrinet for 31 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.

FNORKA
Market Cap
$15.33B$5.18B
Volume
1,120,187490,798
Sector
TechnologyHealth
52-Week High
$746.47$113.08
52-Week Low
$374.91$26.19
Typical Hold Time
31 Days0 Days
Enterprise Value
$14.46B$4.31B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Fabrinet

Fabrinet (FN) trades at $427.82, down 6.26% in the last session amid broader market volatility. The stock shows strong fundamental performance with three consecutive quarterly earnings beats and robust 45% revenue growth in Q4 2026. Technical indicators present a mixed picture with a bullish overall signal but bearish moving averages, while support levels cluster around $407-$441. The company benefits from surging AI data center demand and capacity expansion initiatives.

Fabrinet's outlook remains positive driven by AI infrastructure growth, though risks include customer concentration and margin pressure. Analysts project 64% upside to the $769.50 consensus target with unanimous bullish sentiment (18 buys, 0 sells). The stock offers exposure to high-growth optical manufacturing but faces execution risks in capital expansion.

Oruka Therapeutics Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FN
56% Buy44% Sell
Avg holding period · 31 Days
ORKA
100% Buy0% Sell
Avg holding period · 0 Days

About Fabrinet

Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.

Read more on FN →

About Oruka Therapeutics Inc. Common Stock

Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.

Read more on ORKA →